These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 4005857)

  • 41. Differential expression of genes associated with cell proliferation and apoptosis induced by okadaic acid during the transformation process of BALB/c 3T3 cells.
    Ao L; Liu JY; Gao LH; Liu SX; Yang MS; Huang MH; Cao J
    Toxicol In Vitro; 2008 Feb; 22(1):116-27. PubMed ID: 17935941
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Initiator and promoter induced specific changes in epidermal function and biological potential.
    Yuspa SH; Hennings H; Lichti U
    J Supramol Struct Cell Biochem; 1981; 17(3):245-57. PubMed ID: 7328673
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A role for CCAAT/enhancer binding protein beta-liver-enriched inhibitory protein in mammary epithelial cell proliferation.
    Zahnow CA; Cardiff RD; Laucirica R; Medina D; Rosen JM
    Cancer Res; 2001 Jan; 61(1):261-9. PubMed ID: 11196172
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Malignant transformation of multipotent muscle-derived cells by concurrent differentiation signals.
    Pollett JB; Corsi KA; Weiss KR; Cooper GM; Barry DA; Gharaibeh B; Huard J
    Stem Cells; 2007 Sep; 25(9):2302-11. PubMed ID: 17569791
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suppression of tumorigenicity by the cell-cycle-dependent control of cellular differentiation and proliferation.
    Wille JJ; Scott RE
    Int J Cancer; 1986 Jun; 37(6):875-81. PubMed ID: 3710616
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nonterminal differentiation represses the neoplastic phenotype in spontaneously and simian virus 40-transformed cells.
    Scott RE; Estervig DN; Tzen CY; Minoo P; Maercklein PB; Hoerl BJ
    Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1652-6. PubMed ID: 2537979
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aproliferin: a modulator of proliferative potential.
    Wier ML; Scott RE
    Biofactors; 1988 Jul; 1(2):129-31. PubMed ID: 3076440
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polypeptide changes associated with loss of proliferative potential during the terminal event in differentiation.
    Wier ML; Scott RE
    J Cell Biochem; 1987 Feb; 33(2):137-50. PubMed ID: 2437134
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Coupling of proadipocyte growth arrest and differentiation. II. A cell cycle model for the physiological control of cell proliferation.
    Scott RE; Hoerl BJ; Wille JJ; Florine DL; Krawisz BR; Yun K
    J Cell Biol; 1982 Aug; 94(2):400-5. PubMed ID: 6809770
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrated control of proliferation and differentiation of mesenchymal stem cells.
    Filipak M; Estervig DN; Tzen CY; Minoo P; Hoerl BJ; Maercklein PB; Zschunke MA; Edens M; Scott RE
    Environ Health Perspect; 1989 Mar; 80():117-25. PubMed ID: 2647473
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Regulation of the terminal event in cellular differentiation: biological mechanisms of the loss of proliferative potential.
    Wier ML; Scott RE
    J Cell Biol; 1986 May; 102(5):1955-64. PubMed ID: 2422182
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biological mechanisms for the loss of the differentiated phenotype by non-terminally differentiated adipocytes.
    Hoerl BJ; Wier ML; Scott RE
    Exp Cell Res; 1984 Dec; 155(2):422-34. PubMed ID: 6209152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aproliferin--a human plasma protein that induces the irreversible loss of proliferative potential associated with terminal differentiation.
    Wier ML; Scott RE
    Am J Pathol; 1986 Dec; 125(3):546-54. PubMed ID: 3799819
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell cycle models for the aberrant coupling of growth arrest and differentiation in hyperplasia, metaplasia, and neoplasia.
    Scott RE; Florine DL
    Am J Pathol; 1982 Jun; 107(3):342-8. PubMed ID: 7081388
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aberrant differentiation in mouse skin carcinogenesis.
    Yuspa SH; Kilkenny A; Roop DR
    IARC Sci Publ; 1988; (92):3-10. PubMed ID: 2466787
    [No Abstract]   [Full Text] [Related]  

  • 56. Differentiation, cancer, and anticancer activity.
    Tzen CY; Estervig DN; Minoo P; Filipak M; Maercklein PB; Hoerl BJ; Scott RE
    Biochem Cell Biol; 1988 Jun; 66(6):478-89. PubMed ID: 3048326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Suppression of tumorigenicity by polar compounds that induce terminal differentiation of transformed cells.
    Ciba Found Symp; 1989; 142():71-8. PubMed ID: 2743835
    [No Abstract]   [Full Text] [Related]  

  • 58. Specific expression of proteins and phosphoproteins in 3T3 T mesenchymal stem cells at distinct growth arrest and differentiation states.
    Sparks RL; Zschunke MA; Seibel-Ross EI; Tracy R; Zalitis JG; Boman BM; Hoerl BJ; Scott RE
    Cell Tissue Kinet; 1990 Mar; 23(2):71-87. PubMed ID: 2317836
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mechanisms for the initiation and promotion of carcinogenesis: a review and a new concept.
    Scott RE; Wille JJ; Wier ML
    Mayo Clin Proc; 1984 Feb; 59(2):107-17. PubMed ID: 6366382
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Precancerous stem cells have the potential for both benign and malignant differentiation.
    Chen L; Shen R; Ye Y; Pu XA; Liu X; Duan W; Wen J; Zimmerer J; Wang Y; Liu Y; Lasky LC; Heerema NA; Perrotti D; Ozato K; Kuramochi-Miyagawa S; Nakano T; Yates AJ; Carson WE; Lin H; Barsky SH; Gao JX
    PLoS One; 2007 Mar; 2(3):e293. PubMed ID: 17356702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.